vimarsana.com

Latest Breaking News On - Vaxart - Page 2 : vimarsana.com

Vaxart (NASDAQ:VXRT) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Vaxart (NASDAQ:VXRT – Free Report) in a research report released on Thursday, Benzinga reports. The firm currently has a $4.00 target price on the biotechnology company’s stock. Vaxart Price Performance Shares of NASDAQ VXRT opened at $0.78 on Thursday. The stock has a market capitalization of […]

Vaxart (VXRT) Reports Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate

Vaxart (VXRT) Reports Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Strong week for Vaxart (NASDAQ:VXRT) shareholders doesn t alleviate pain of three-year loss

Vaxart, Inc. ( NASDAQ:VXRT ) shareholders should be happy to see the share price up 10% in the last week. But that is.

Vaxart, Inc (NASDAQ:VXRT) Q2 2023 Earnings Call Transcript

Vaxart, Inc. (NASDAQ:VXRT) Q2 2023 Earnings Call Transcript August 3, 2023 Vaxart, Inc. misses on earnings expectations. Reported EPS is $-0.16 EPS, expectations were $0.19. Operator: Greetings, and welcome to the Vaxart Business Update and Second Quarter 2023 Financial Results Conference Call. A question-and-answer session will follow management’s opening remarks. Individual investors may submit written […]

Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement

26.06.2023 - SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) - Vaxart, Inc. (Nasdaq: VXRT) today held its Annual Meeting of Shareholders in a virtual-only format. Preliminary results from the Annual Meeting indicate that all four proposals were . Seite 1

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.